Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Data from total proteomic and phosphoproteomic sequencing

ABSTRACT: To assess the function of the target gene, we performed knockdown in A549 and H1975 cells, followed by phosphoproteomic and proteomic profiling via sequencing-based analysis.

ORGANISM(S): Homo Sapiens

SUBMITTER: Pengquan Zeng

PROVIDER: PXD082121 | iProX | Mon Aug 03 00:00:00 GMT+01:00 2026

REPOSITORIES: iProX

ACCESS DATA

Json Xml

Similar Datasets

Linking oncogenic signaling to transcriptional changes by epigenomic data in a cell line model of human glioblastoma

Project description:We present a computational method for building a regulatory network from global phosphoproteomic and transcription profiling data. To recover the critical missing links between signaling events and transcriptional responses, we relate changes in chromatin accessibility to changes in expression and then uses these links to connect proteomic and transcriptome data. We applied our approach to integrate epigenomic, phosphoproteomic and transcriptome changes induced by the variant III mutation of the epidermal growth factor receptor (EGFRvIII) in a cell line model of glioblastoma multiforme (GBM). Genome-wide DNase I hypersensitivity followed by sequencing (DNase-Seq) to measure chromatin accessibility in a cell line derived from the U87MG glioblastoma cell line to express high level of EGFRvIII (U87H; 2 million copies of EGFRvIII per cell) and a control cell line expressing kinase dead EGFRvIII (U87DK; 2 million kinase dead EGFRvIII per cell). A prediction from the computational method, the transcriptional co-regulator p300, was experimentally validated by chromatin immunoprecipitation followed by sequencing (ChIP-Seq).

2013-01-01 | E-GEOD-36900 | biostudies-arrayexpress

Identification of Biomarkers in Myocardial Hypertrophy and Fibrosis via Integrated Transcriptomic and Phosphoproteomic Profiling

Project description:Myocardial hypertrophy and fibrosis (MHF) are key structural changes in adverse cardiac remodeling. They are commonly observed in hypertension, metabolic disorders, and cardiomyopathies. These processes contribute to heart failure and sudden death, yet their molecular mechanisms remain unclear. We established in vivo and in vitro models of MHF and performed transcriptomic and label-free phosphoproteomic sequencing. These data were integrated with public single-cell RNA sequencing datasets. This multi-tier strategy enabled us to move beyond bulk-tissue signals and prioritize candidates based on cross-omics concordance and cell-type-specific expression. We identified five candidate biomarkers, CLIP2, PLA2G4A, PRRX1, SLAIN2, and XPO1. These candidates showed coordinated upregulation or downregulation at both the transcriptomic and phosphoproteomic levels. They were also specifically enriched in disease-relevant cardiac cell populations, including cardiomyocytes and fibroblasts. PRRX1 and PLA2G4A were enriched in fibrogenic fibroblast subsets and increased along activation trajectories. XPO1 and SLAIN2 were downregulated in cardiomyocytes and fibroblasts, suggesting impaired nuclear export and cytoskeletal regulation. Molecular docking revealed flurandrenolide and selinexor as potential modulators of PLA2G4A and XPO1 respectively. However, their cardiovascular safety and efficiency remain uncertain. Notably, the therapeutic implications of XPO1 modulation appear context-dependent, warranting careful evaluation of its functional role in specific MHF etiologies. Overall, these findings highlight novel targets and provide mechanistic insights into MHF progression.

2026-06-18 | GSE326552 | GEO

Transcriptome profiling (RNA-seq) of wild type and MYOCD Knockdown in human lung cancer cell line A549.

Project description:Purpose: Next-generation sequencing (NGS) has revolutionized systems-based analysis of cellular pathways. The goals of this study are to compare transcriptome profiling (RNA-seq) of wild type and MYOCD Knockdown in human lung cancer cell line A549. Methods: mRNA profiles of wild type（WT） and Dox inducible MYOCD Knockdown (MYOCD−/−) human lung cancer cell line A549 were generated by deep sequencing, using Illumina GAIIx. The sequence reads that passed quality filters were analyzed at the transcript isoform level with two methods: Burrows–Wheeler Aligner (BWA) followed by ANOVA (ANOVA) and TopHat followed by Cufflinks. qRT–PCR validation was performed using TaqMan and SYBR.

2019-03-30 | GSE128918 | GEO

Transcriptome sequencing of A549 cells

Project description:We analyzed the global effect of SOX9 knockdown and TGFB1 treatment by sequencing the transcriptomes of A549 cells transfected with siSOX9 or control siRNA and treated with TGFB1.

2024-01-15 | GSE217880 | GEO

Consequence of knock down of CBX7 in multiple cell lines

Project description:We conduct an experiment where CBX7 is knocked down in 4 different cell lines: A549, H1299, K562 and THP-1. After culturing these cell lines for three days with or without knockdown of CBX7, we then perform RNA sequencing (RNA-seq) to assess the impact.

2024-03-01 | GSE254063 | GEO

RNA-Seq data from A549 cells

Project description:We report the transcription factor HOXB9 directly increases the expression of many target genes by performing RNA sequencing using HOXB9 stable knockdown A549 Lung adenocarcinoma cell line and HOXB9(WT/T133A) cell line.

2021-12-21 | GSE176286 | GEO

Proteomic and phosphoproteomic data

Project description:Proteomic and phosphoproteomic data

2020-01-08 | OEX00002200 | NODE

Total RNA sequencing of AKAP12 knockdown cells

Project description:Total RNA sequencing of AKAP12 knockdown cells

| PRJNA616288 | ENA

Total RNA sequencing of RBMS1 knockdown cells

Project description:Total RNA sequencing of RBMS1 knockdown cells

| PRJNA616287 | ENA

Identification of Biomarkers in Myocardial Hypertrophy and Fibrosis via Integrated Transcriptomic and Phosphoproteomic Profiling,Proteome sequencing

2026-06-15 | PXD076291 | Pride